RAB40AL was first reported in relation to X-linked syndromic intellectual disability in 2012 (PMID: 22581972). The five individuals, from three unrelated families, reported to date with claims of causative variants in RAB40AL presented with phenotypes including intellectual disability, sensorineural hearing loss, short stature, and craniofacial dysmorphisms. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism, inheritance pattern, or phenotypic variability between these cases. Therefore, for the purposes of this curation, all of the reported disease entities, including Martin-Probst X-linked mental retardation (OMIM: 300519), will be considered together under the general term X-linked syndromic intellectual disability.
At this time, only two unique variants have been reported in affected individuals The first published variant (PMID: 22581972), a dinucleotide missense change, is unlikely to cause Mendelian disease for several reasons. First, this variant has been observed at high frequencies in control populations of unaffected adult males (625 individuals including 10 homozygotes in the gnomAD population database (v.2.1.1)) (PMIDs: 25044830, 25370018). Further, there are reports of this variant not segregating with phenotype in families (PMIDs: 25044830, 25644381), and instances of this variant in families with alternate genetic explanations for their phenotypes (PMIDs: 25370018, 25644381). The second reported variant is a small, in-frame, deletion-insertion with no supportive functional data (PMID: 30945278). Given the dearth of experimental evidence linking RAB40AL with disease, and the scarcity of plausible reports of disease-causing variants in humans, the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel awarded 0 points for this variant.
Of note, the potential role for truncating variants in RAB40AL (a single exon gene) in disease has also been questioned. In response to the original 2012 publication, Kalscheur et al. published a letter describing a family with X-linked intellectual disability and a hemizygous frameshift variant in RAB40AL in an unaffected male, and in the homozygous state in several unaffected females (https://jmg.bmj.com/content/49/5/332.responses#rab40al-loss-of-function-mutation-does-not-cause-x-linked-intellectual-disability).
Given the data regarding both truncating and non-truncating variants in RAB40AL, there is convincing evidence refuting the relationship between RAB40AL and X-linked syndromic intellectual disability, which significantly outweighs the evidence supporting the relationship. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on June 15, 2021 (SOP Version 8).
The GenCC data are available free of restriction under a CC0 1.0 Universal (CC0 1.0) Public Domain Dedication. The GenCC requests that you give attribution to GenCC and the contributing sources whenever possible and appropriate. The accepted Flagship manuscript is now available from Genetics in Medicine (https://www.gimjournal.org/article/S1098-3600(22)00746-8/fulltext).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The GenCC does not independently verify the submitted information. Though the information is obtained from sources believed to be reliable, no warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, reliability or usefulness of any information. This disclaimer applies to both isolated and aggregate uses of the information. The information is provided on an "as is" basis, collected through periodic submission and therefore may not represent the most up-to-date information from the submitters. If you have questions about the medical relevance of information contained on this website, please see a healthcare professional; if you have questions about specific gene-disease claims, please contact the relevant sources; and if you have questions about the representation of the data on this website, please contact gencc@thegencc.org.